Danaher Corp (DHR) Reports Q3 2026 Earnings, Highlights Growth S
Danaher Corp (DHR) reported Q3 2026 sales of $6.6B, with core growth (excluding respiratory revenue) up 5.5%. CFO Matthew Gugino projected Q4 core revenue growth of 4-5% and an adjusted operating margin of 29.5%. The company is trading at $233.86, slightly undervalued by 1.0% according to GF Value™. Danaher's GF Score™ is 82/100, indicating strong financial health. Insider activity shows significant selling, while 26 premium gurus hold the stock.
How this was made
The 30-second read
Why it matters
The earnings beat and forward guidance provide a fresh data point for valuation models and may trigger short‑term buying.
Market read
First‑report earnings release for a large‑cap healthcare equipment maker; provides actionable insight for traders.
What to watch
The high trailing P/E of 41.5x suggests the stock may already be priced for growth, limiting upside.
Background
Danaher is a diversified science and technology company with segments in life sciences, diagnostics, and biotechnology.
Ticker impact
Danaher reported Q3 2026 earnings with $6.6B sales and provided Q4 core revenue guidance of 4-5% and an adjusted operating margin near 29.5%.
likely upward pressure as the market prices in better‑than‑expected growth and margin outlook
The company posted solid core revenue growth and issued optimistic Q4 guidance, which typically supports a price rally.
Market effects
Positive earnings may boost sentiment in the broader healthcare and life‑sciences equipment sector.
U.S. market participants may view the results as a sign of resilience in the sector.
Limited to investors tracking large‑cap U.S. healthcare stocks.
Counterpoint
Insider selling of $258M could signal concerns about near‑term performance despite the upbeat guidance.
Key entities
- companyDanaher Corp
Global science and technology firm reporting Q3 2026 results.
- executiveJulie Montgomery
CEO who is steering the company's growth strategy.
